SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques
Author Information
Author(s): Masahiro Ono, Hideo Saji
Primary Institution: Graduate School of Pharmaceutical Sciences, Kyoto University
Hypothesis
The development of radiotracers for in vivo imaging of β-amyloid plaques in Alzheimer's disease is crucial for diagnosis and therapy evaluation.
Conclusion
The study reviews the current state of SPECT imaging agents for detecting β-amyloid plaques, highlighting their potential for improving Alzheimer's disease diagnosis.
Supporting Evidence
- The presence of β-amyloid aggregates is a hallmark of Alzheimer's disease.
- Nuclear imaging techniques like SPECT can facilitate the diagnosis of Alzheimer's disease.
- Several promising SPECT imaging agents have been developed but require further optimization.
Takeaway
This study looks at special agents that can help doctors see harmful proteins in the brains of people with Alzheimer's disease, which can help them diagnose and treat the illness better.
Methodology
The paper reviews various SPECT imaging agents developed for detecting β-amyloid plaques in Alzheimer's disease, discussing their chemical properties and effectiveness.
Limitations
Progress in developing SPECT imaging agents is less advanced compared to PET agents, and many agents have not been tested in vivo.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website